Athersys (NASDAQ:ATHX) vs. Vectura Group (OTCMKTS:VEGPF) Head-To-Head Review

Volatility & Risk

Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the S&P 500. Comparatively, Vectura Group has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

Profitability

This table compares Athersys and Vectura Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Vectura Group	N/A	N/A	N/A

Insider and Institutional Ownership

19.4% of Athersys shares are held by institutional investors. 0.0% of Athersys shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Athersys and Vectura Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146,000.00	0.00	-$72.53 million	($2.03)	N/A
Vectura Group	$244.76 million	4.37	$157.16 million	$0.26	6.81

Vectura Group has higher revenue and earnings than Athersys. Athersys is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.

Summary

Vectura Group beats Athersys on 6 of the 8 factors compared between the two stocks.

About Athersys

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

About Vectura Group

Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.